A Review of the Safety of Interleukin-17A Inhibitor Secukinumab

Secukinumab is an anti-interleukin (IL)-17A IgG1-κ monoclonal antibody approved for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Its efficacy is well documented, but the complete safety profile of secukinumab, especially on long-term use, needs to be studied. IL-17 inhibitors increase...

Descripción completa

Detalles Bibliográficos
Autores principales: Eshwar, Vishnu, Kamath, Ashwin, Shastry, Rajeshwari, Shenoy, Ashok K., Kamath, Priyanka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695424/
https://www.ncbi.nlm.nih.gov/pubmed/36355537
http://dx.doi.org/10.3390/ph15111365

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695424/
https://www.ncbi.nlm.nih.gov/pubmed/36355537
http://dx.doi.org/10.3390/ph15111365

Ejemplares similares